文献速递淋巴瘤

IGLV3-21R110 定义一种侵袭性生物学亚型:表观遗传中间型慢性淋巴细胞白血病

IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
PubMed 文献 · Blood · 2021-01-01

该研究对 584 例慢性淋巴细胞白血病(CLL)病例进行免疫球蛋白基因分析,检测 IGLV3-21R110 突变,并关联表观遗传亚型与临床结局。结果显示 IGLV3-21R110 见于 6.5% 病例,富集于中间型表观遗传亚型(i-CLL),且该突变定义了一个独立于 IGHV 突变状态和表观遗传亚型的不良预后亚组。

要点

  • IGLV3-21R110 见于 6.5% 的 CLL 病例,在 i-CLL 中占 38%。
  • 携带 IGLV3-21R110 的 i-CLL 首次治疗时间短,总生存与 n-CLL/IGHV 未突变患者相似。
  • 该突变定义的不良预后独立于 IGHV 突变状态和表观遗传亚型。

核心结论

  • IGLV3-21R110 定义了一个具有特定生物学特征且预后不良的 CLL 亚组,该预后独立于 IGHV 突变状态和表观遗传亚型。

研究设计与样本

  • 对 584 例 CLL 病例采用全基因组/外显子组和 RNA 测序进行免疫球蛋白基因特征分析。
  • 基于甲基化特征将 CLL 分为 naïve-like(n-CLL)、intermediate(i-CLL)和 memory-like(m-CLL)三种表观遗传亚型。

主要发现

  • IGLV3-21R110 在 6.5% 的病例中检出:79 例 i-CLL 中 30 例(38%),291 例 m-CLL 中 5 例(1.7%),189 例 n-CLL 中 1 例(0.5%)。
  • 所有 stereotype subset 2 病例均携带 IGLV3-21R110,而 62% 的 IGLV3-21R110 i-CLL 病例为非 stereotyped BCR 免疫球蛋白。
  • IGLV3-21R110 i-CLL 的 SF3B1 和 ATM 突变数及驱动改变总数显著更高;但 R110 突变在 1 例 i-CLL 中是唯一改变,在 3 例中仅伴 del(13q)。
  • IGLV3-21R110 i-CLL 转录组类似 n-CLL/IGHV 未突变 CLL,包括 WNT5A/B 过表达特征;缺乏 IGLV3-21R110 的 i-CLL 则类似 m-CLL/IGHV 突变 CLL。
  • IGLV3-21R110 i-CLL 患者首次治疗时间短,总生存与 n-CLL/IGHV 未突变患者相似;非 IGLV3-21R110 i-CLL 患者预后良好,类似 m-CLL/IGHV 突变患者。

临床怎么用

  • 对 CLL 患者可检测 IGLV3-21R110 以识别独立于 IGHV 突变状态和表观遗传亚型的不良预后亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology. IGLV3-21-expressing B cells may acquire a single point mutation (R110) that triggers autonomous BCR signaling, conferring aggressive behavior. Epigenetic studies have defined 3 CLL subtypes based on methylation signatures reminiscent of naïve-like (n-CLL), intermediate (i-CLL), and memory-like (m-CLL) B cells with different biological features. i-CLL carries a borderline IGHV mutational load and significantly higher use of IGHV3-21/IGLV3-21. To determine the clinical and biological features of IGLV3-21R110 CLL and its relationship to these epigenetic subtypes, we characterized the immunoglobulin gene of 584 CLL cases using whole-genome/exome and RNA sequencing. IGLV3-21R110 was detected in 6.5% of cases: 30 (38%) of 79 i-CLLs, 5 (1.7%) of 291 m-CLLs, and 1 (0.5%) of 189 n-CLLs. All stereotype subset 2 cases carried IGLV3-21R110, whereas 62% of IGLV3-21R110 i-CLL cases had nonstereotyped BCR immunoglobulins. IGLV3-21R110 i-CLL had a significantly higher number of SF3B1 and ATM mutations and total number of driver alterations. However, the R110 mutation was the sole alteration in 1 i-CLL and was accompanied only by del(13q) in 3. Although IGHV mutational status varied, IGLV3-21R110 i-CLL transcriptomically resembled n-CLL/unmutated IGHV CLL with a specific signature including WNT5A/B overexpression. In contrast, i-CLL lacking IGLV3-21R110 mirrored m-CLL/mutated IGHV. Patients with IGLV3-21R110 i-CLL had a short time to first treatment and overall survival similar to those of n-CLL/unmutated IGHV patients, whereas patients with non-IGLV3-21R110 i-CLL had a good prognosis similar to that of patients with m-CLL/mutated IGHV. IGLV3-21R110 defines a CLL subgroup with specific biological features and an unfavorable prognosis independent of IGHV mutational status and epigenetic subtype.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nadeu F, Royo R, Clot G, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021. PMID: 33211804. doi:10.1182/blood.2020008311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。